Why Your Doctor Won't Prescribe It — and It's Not Why You Think

You've done the research. You've read the studies. You know that tirzepatide, semaglutide, and testosterone replacement therapy have legitimate, well-documented clinical applications for people exactly like you — shift workers, high-stress jobs, bodies that never quite get to recover. You've worked up the nerve to bring it up with your doctor. And they change the subject, hedge, or offer you a referral to a specialist with a six-month waitlist.

It feels like you're asking for something sketchy. You're not. So what's actually going on?

The short version: your doctor's hands are tied in ways they probably won't — and sometimes legally can't — explain to you.

The System Wasn't Built for You

Most people assume medicine is a meritocracy of outcomes. The best treatment for the patient wins. That's a flattering picture of healthcare, and it's not especially accurate in 2026.

The real system runs on formularies, prescribing efficiency scores, and network contracts that most patients have never heard of. Your insurer doesn't just pay for care — they actively shape what care gets offered to you. And they do it in ways that are almost impossible to see from the patient's seat.

"Your doctor's prescribing habits are being scored, tracked, and used to determine their network status and reimbursement rates. They know it. They just can't tell you."

Here's one mechanism: insurers calculate something called a Prescribing Efficiency Index — a score that tracks how often a provider prescribes cheaper generics and insurer-preferred drugs versus anything else. Doctors who score well get faster approvals and better reimbursement. Doctors who score poorly face prior authorization delays, audits, and eventually the threat of network exclusion.

GLP-1 medications like tirzepatide and semaglutide are, by any measure, not the cheap option. TRT is a gray zone that triggers red flags on its own. When your doctor looks at you and hears your request, part of what they're calculating — consciously or not — is what that prescription does to their score.

The "Step Therapy" Trap

Even when a doctor is fully on board, the system has another tool: step therapy, or "fail first" protocols. Before your insurer will authorize a GLP-1 or any specialty medication, you're often required to try and fail on cheaper alternatives first. A diet program you didn't need. A generic that doesn't address your actual issue. Sometimes you need to demonstrate 30 days of failure before the next step is even considered.

Thirty days. For a first responder who works 24-hour shifts, whose cortisol is chronically elevated, whose sleep schedule is chaos. Thirty days of documented failure as a bureaucratic prerequisite.

Your Doctor Isn't the Villain

This is worth saying clearly: most primary care physicians actually want to help you. They went into medicine for the right reasons. But they're operating inside a structure that penalizes clinical independence.

The administrative weight alone is crushing. Prior authorization paperwork for a single specialty prescription can take hours. Multiply that by a full patient panel and you understand why doctors default to the path of least resistance — not because they're lazy, but because the system has made the right call extraordinarily expensive in time and risk.

There's also the sheer administrative friction. Initiating a new treatment protocol — even a well-evidenced one — means documentation, follow-up scheduling, prior auth battles, and a paper trail your PCP has to manage on top of a full patient panel. The incentive isn't to be bold. The incentive is to refer, wait, and let someone else carry the administrative load.

"The incentive isn't to be bold. The incentive is to refer, wait, and cover yourself. The patient's urgency doesn't register in that calculus."

The Part Nobody Talks About: Pharmaceutical Access Is Political

There's a layer beneath the insurance layer that most people never see: pharmacy benefit managers (PBMs) — the middlemen who negotiate drug pricing between manufacturers and insurers. The three largest PBMs control the majority of prescriptions filled in the United States, and they have enormous influence over what ends up on a preferred formulary.

When tirzepatide or branded semaglutide isn't on your plan's preferred formulary, it's not an accident. It's a negotiated outcome. The manufacturer didn't pay the right rebate, or the PBM has a competing product they've cut a better deal on. Meanwhile, your doctor gets yelled at by the prior auth system every time they try to route around it.

Compounded versions of these medications — which are legal, which are prepared by FDA-registered pharmacies, which are used by legitimate clinical providers every day — exist partly as a response to this dysfunction. They give providers a way to get patients the medication they actually need without running the gauntlet.

What This Means If You're a First Responder

The dysfunction hits harder if you're in public safety. Your schedule makes traditional healthcare nearly impossible. You can't take appointments at 2pm on a Tuesday. You can't do a three-visit referral process that spans four months. You age faster than a desk job. Your body takes more punishment, your cortisol stays higher, your sleep architecture is wrecked. The clinical evidence for proactive hormone support, weight management intervention, and metabolic care is stronger for your population — and the access is worse.

Traditional healthcare wasn't designed around a 24-hour shift schedule. It wasn't designed around someone who needs to be physically capable of pulling bodies out of a burning building, and who needs a healthcare system that treats that seriously.

The Numbers Don't Lie

Here's a stat that should make you stop scrolling: roughly 20% of men over 60, 30% over 70, and 50% over 80 have clinically low testosterone. The Hypogonadism in Males study — which looked at men 45 and older visiting primary care offices — found a prevalence rate of nearly 39%. Yet only about 5% of hypogonadal men actually receive testosterone replacement therapy.

The ProPublica Prescriber Checkup, which analyzed CMS Medicare Part D data, recorded roughly 497,000 testosterone cypionate claims across all of Medicare in 2016. Medicare covers roughly 30 million men. Even using the most conservative prevalence estimates, the gap between who likely needs treatment and who's actually receiving it runs into the millions.

That's not a gap caused by patients not wanting treatment. That's a gap caused by a system that makes treatment hard to access, hard to justify on paper, and professionally risky for the doctors who try.

It's Okay to Skip the Chain of Command

In your job, chain of command exists for a reason. In healthcare, it often just means waiting longer for something you already know you need.

That doesn't mean firing your PCP. It means recognizing that for specific, evidence-backed treatments — GLP-1s, TRT, sexual health — the traditional referral chain isn't protecting you. It's just slow. Telehealth platforms built for this gap are staffed by licensed independent providers who can evaluate, prescribe, and follow up without the insurance network politics, the formulary gatekeeping, or the three-month specialist waitlist.

Your doctor isn't refusing to help you because they don't care. They're navigating a system that has made the right care extremely difficult to deliver. Going around that system isn't disloyal to your doctor. It's just practical.

RespondWell connects first responders with licensed independent providers who can evaluate, prescribe, and support without the waiting room, the referral merry-go-round, or the formulary gatekeeping. If you qualify, you get care. That's the whole model.

Disclaimer: This content is for informational purposes only and does not constitute medical advice.